See more : PT Dayamitra Telekomunikasi Tbk. (MTEL.JK) Income Statement Analysis – Financial Results
Complete financial analysis of AVROBIO, Inc. (AVRO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AVROBIO, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Nobia AB (publ) (NOBI.ST) Income Statement Analysis – Financial Results
- Wind Buzz Technologies Ltd (WNBZ.TA) Income Statement Analysis – Financial Results
- Great Microwave Technology Co., Ltd. (688270.SS) Income Statement Analysis – Financial Results
- Tokuyama Corporation (TKYMF) Income Statement Analysis – Financial Results
- PrismOne Group, Inc. (PMOZ) Income Statement Analysis – Financial Results
AVROBIO, Inc. (AVRO)
About AVROBIO, Inc.
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 617.00K | 4.17M | 1.40M | 1.21M | 850.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -617.00K | -4.17M | -1.40M | -1.21M | -850.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 47.08M | 72.19M | 83.11M | 87.24M | 54.97M | 35.10M | 15.19M | 2.66M |
| General & Administrative | 22.69M | 33.25M | 35.73M | 32.99M | 20.84M | 11.15M | 3.20M | 1.96M |
| Selling & Marketing | 23.94M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 23.97M | 33.25M | 35.73M | 32.99M | 20.84M | 11.15M | 3.20M | 1.96M |
| Other Expenses | 0.00 | -456.00K | -285.00K | 516.00K | 2.84M | -118.00K | -19.00K | -6.00K |
| Operating Expenses | 71.05M | 105.43M | 118.84M | 120.23M | 75.81M | 46.24M | 18.39M | 4.63M |
| Cost & Expenses | 71.67M | 105.43M | 118.84M | 120.23M | 75.81M | 46.24M | 18.39M | 4.63M |
| Interest Income | 2.42M | 299.00 | 0.00 | 719.00K | 2.93M | 1.73M | 57.00K | 6.00K |
| Interest Expense | 2.42M | 299.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 617.00K | 1.44M | 1.40M | 1.21M | 850.00K | 380.00K | 45.00K | 39.00K |
| EBITDA | -71.05M | -105.43M | -118.84M | -120.23M | -75.81M | -46.24M | -18.04M | -4.59M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -71.67M | -105.43M | -118.84M | -120.23M | -75.81M | -46.24M | -18.39M | -4.63M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.34M | -456.00K | -285.00K | 516.00K | 2.84M | -118.00K | -262.00K | -39.00K |
| Income Before Tax | 12.53M | -105.89M | -119.13M | -119.71M | -72.97M | -46.36M | -18.65M | -4.66M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 377.00K | 157.00K | -1.40M | -1.21M | -850.00K | -118.00K | 243.00K | -6.00K |
| Net Income | 12.16M | -106.05M | -117.73M | -118.51M | -72.12M | -46.36M | -18.65M | -4.66M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.27 | -2.42 | -2.75 | -3.27 | -2.63 | -3.45 | -1.15 | -0.67 |
| EPS Diluted | 0.27 | -2.42 | -2.75 | -3.27 | -2.63 | -3.45 | -1.15 | -0.67 |
| Weighted Avg Shares Out | 44.33M | 43.74M | 42.85M | 36.21M | 27.43M | 13.44M | 16.19M | 6.92M |
| Weighted Avg Shares Out (Dil) | 44.57M | 43.74M | 42.85M | 36.21M | 27.43M | 13.44M | 16.19M | 6.92M |
AVROBIO Presents New Preclinical Data on Lentiviral Gene Therapy Program for Pompe Disease at ASGCT 2020
AVROBIO Reports Updated Clinical Data from Investigational Gene Therapy Programs for Fabry Disease and Cystinosis
Atara Biotherapeutics Announces Appointment of Cell & Gene Therapy Expert Maria Grazia Roncarolo, MD to Board of Directors
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
Catalent, Inc. (CTLT) CEO John Chiminski on Q3 2020 Results - Earnings Call Transcript
Avrobio Magenta Collaboration, And Other News: The Good, Bad And Ugly Of Biopharma
AVROBIO Reports 1Q 2020 Financial Results and Provides Business Update
AVROBIO to Present New Clinical and Preclinical Data at Upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 12-15, 2020
AVROBIO to Collaborate with Saladax Biomedical on New High-Speed Diagnostic Assay Used with Busulfan Conditioning to Enable Widespread Commercialization of AVROBIO’s Proprietary Platform Globally
Source: https://incomestatements.info
Category: Stock Reports